Switching from IV to injectable nerve inflammation treatment at home

This trial is tracking how well Hizentra® works when patients switch from receiving immunoglobulin through an IV in the hospital to injecting it under the skin at home. The study will follow about 100 adults with a rare nerve disease called CIDP to understand what happens in real-world practice—including whether the medication works just as well, what side effects people experience, and what the best way to make the switch is.

Doctors know this medication can work for CIDP, but most evidence comes from small studies in hospitals. This trial exists to see how well the treatment actually works when patients use it at home on their own, and to understand the best practices for helping people make the transition from IV to injectable therapy.